199 related articles for article (PubMed ID: 32461254)
1. Phase-separated condensate-aided enrichment of biomolecular interactions for high-throughput drug screening in test tubes.
Zhou M; Li W; Li J; Xie L; Wu R; Wang L; Fu S; Su W; Hu J; Wang J; Li P
J Biol Chem; 2020 Aug; 295(33):11420-11434. PubMed ID: 32461254
[TBL] [Abstract][Full Text] [Related]
2. Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.
Nirantar SR; Li X; Siau JW; Ghadessy FJ
Biosens Bioelectron; 2014 Jun; 56():250-7. PubMed ID: 24508816
[TBL] [Abstract][Full Text] [Related]
3. Molecular rotors as conditionally fluorescent labels for rapid detection of biomolecular interactions.
Goh WL; Lee MY; Joseph TL; Quah ST; Brown CJ; Verma C; Brenner S; Ghadessy FJ; Teo YN
J Am Chem Soc; 2014 Apr; 136(17):6159-62. PubMed ID: 24494589
[TBL] [Abstract][Full Text] [Related]
4. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
5. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
[TBL] [Abstract][Full Text] [Related]
6. Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.
Jacoby E; Boettcher A; Mayr LM; Brown N; Jenkins JL; Kallen J; Engeloch C; Schopfer U; Furet P; Masuya K; Lisztwan J
Methods Mol Biol; 2009; 575():173-94. PubMed ID: 19727615
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partner.
Fry DC
Curr Pharm Des; 2012; 18(30):4679-84. PubMed ID: 22650256
[TBL] [Abstract][Full Text] [Related]
8. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.
Fry DC; Graves B; Vassilev LT
Methods Enzymol; 2005; 399():622-33. PubMed ID: 16338385
[TBL] [Abstract][Full Text] [Related]
9. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
10. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
11. Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.
Liu L; Bernard D; Wang S
Methods Mol Biol; 2015; 1278():567-85. PubMed ID: 25859977
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
Miyazaki M; Kawato H; Naito H; Ikeda M; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem Lett; 2012 Oct; 22(20):6338-42. PubMed ID: 22995624
[TBL] [Abstract][Full Text] [Related]
13. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.
Mungamuri SK; Qiao RF; Yao S; Manfredi JJ; Gu W; Aaronson SA
Cell Rep; 2016 Mar; 14(11):2528-37. PubMed ID: 26971997
[TBL] [Abstract][Full Text] [Related]
14. A facile method to screen inhibitors of protein-protein interactions including MDM2-p53 displayed on T7 phage.
Ishi K; Sugawara F
Biochem Pharmacol; 2008 May; 75(9):1743-50. PubMed ID: 18384755
[TBL] [Abstract][Full Text] [Related]
15. An antibody-free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST-HDM2 recombinant protein.
Costa B; Grillone AF; Salvetti A; Rocchiccioli S; Iacopetti P; Daniele S; Da Pozzo E; Campiglia P; Novellino E; Martini C; Rossi L
Drug Test Anal; 2013 Jul; 5(7):596-601. PubMed ID: 23733564
[TBL] [Abstract][Full Text] [Related]
16. Phase Separation-Based Biochemical Assays for Biomolecular Interactions.
Pei G; Zhou M; Xu W; Wang J; Li P
Methods Mol Biol; 2023; 2563():225-236. PubMed ID: 36227476
[TBL] [Abstract][Full Text] [Related]
17. Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.
D'Alessandro PL; Buschmann N; Kaufmann M; Furet P; Baysang F; Brunner R; Marzinzik A; Vorherr T; Stachyra TM; Ottl J; Lizos DE; Cobos-Correa A
Angew Chem Int Ed Engl; 2016 Dec; 55(52):16026-16030. PubMed ID: 27874234
[TBL] [Abstract][Full Text] [Related]
18. A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.
Li J; Zhang S; Gao L; Chen Y; Xie X
J Biomol Screen; 2011 Apr; 16(4):450-6. PubMed ID: 21471462
[TBL] [Abstract][Full Text] [Related]
19. A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.
Lundholt BK; Heydorn A; Bjørn SP; Praestegaard M
Assay Drug Dev Technol; 2006 Dec; 4(6):679-88. PubMed ID: 17199506
[TBL] [Abstract][Full Text] [Related]
20. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
